Post-viral symptoms and conditions are more frequent in COVID-19 than influenza, but not more persistent

Author:

Tesch Falko1ORCID,Ehm Franz1ORCID,Loser Friedrich Loser2,Vivirito Annika3,Wende Danny4ORCID,Batram Manuel5,Bechmann Lars6,Buschmann Tilo7,Menzer Simone6,Ludwig Marion8,Roessler Martin4ORCID,Seifert Martin1,Margolis Giselle Sarganas9,Reitzle Lukas9,König Christina2,Schulte Claudia4,Hertle Dagmar4ORCID,Ballesteros Pedro4,Baßler Stefan7,Bertele Barbara2,Bitterer Thomas6,Riederer Cordula10,Sobik Franziska10,Scheidt-Nave Christa11,Schmitt Jochen1

Affiliation:

1. University Hospital and Faculty of Medicine Carl Gustav Carus at TU Dresden

2. Techniker Krankenkasse

3. InGef - Institute for Applied Health Research Berlin GmbH

4. BARMER Institut für Gesundheitssystemforschung (bifg)

5. Vandage GmbH

6. IKK classic

7. AOK PLUS

8. InGef - Institute for Applied Health Research Berlin

9. Robert Koch Institute

10. DAK-Gesundheit

11. Robert Koch Institut

Abstract

Abstract Post-viral symptoms have long been known in the medical community but have received more public attention during the COVID-19 pandemic. Many post-viral symptoms were reported as particularly frequent after SARS-CoV-2 infection. However, there is still a lack of evidence regarding the specificity, frequency and persistence of these symptoms in comparison to other viral infectious diseases such as Influenza. We addressed this topic by investigating a large population-based cohort based on German routine healthcare data. We matched 573,791 individuals with a PCR-test confirmed SARS-CoV-2 infection from the year 2020 to contemporary controls without SARS-CoV-2 infection and controls from the last Influenza outbreak in 2018 and followed them up to 18 months. We found that post-viral symptoms as defined for COVID-19 by the WHO as well as tissue damage were more frequent among the COVID-19 cohort than the Influenza cohort. Persistence of post-viral symptoms was however similar between COVID-19 and Influenza. We conclude that post-viral symptoms following SARS-CoV-2 infection constitute a substantial disease burden as they are frequent and often persist for many months. As COVID-19 is becoming endemic, the disease must not be trivialized. Research should focus on the development of effective treatments for post-viral symptoms.

Publisher

Research Square Platform LLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3